L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature.
Ann Oncol
; 20(1): 110-6, 2009 Jan.
Article
en En
| MEDLINE
| ID: mdl-18701429
ABSTRACT
BACKGROUND:
Extranodal natural killer (NK)/T-cell lymphoma, nasal type, and aggressive NK-cell leukemia are highly aggressive diseases with a poor outcome. PATIENTS ANDMETHODS:
We report a multicentric French retrospective study of 15 patients with relapsed, refractory, or disseminated disease, treated with L-asparaginase-containing regimens in seven French centers. Thirteen patients were in relapse and/or refractory and 10 patients were at stage IV.RESULTS:
All but two of the patients had an objective response to L-asparaginase-based treatment. Seven patients reached complete remission and only two relapsed.CONCLUSION:
These data, although retrospective, confirm the excellent activity of L-asparaginase-containing regimens in refractory extranodal NK/T-cell lymphoma and aggressive NK-cell leukemia. Therefore, L-asparaginase-based regimen should be considered as a salvage treatment, especially for patients with disseminated disease. First-line L-asparaginase combination therapy for extranodal NK/T-cell lymphoma and aggressive NK-cell leukemia should be tested in prospective trials.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Asparaginasa
/
Leucemia
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Linfoma Extranodal de Células NK-T
Tipo de estudio:
Evaluation_studies
/
Observational_studies
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2009
Tipo del documento:
Article